New Study
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure that creates challenges for patients and caregivers. Immune checkpoint inhibitors have brought hope to patients, but new data from Australia is raising questions about their safety and effectiveness. In order to make informed decisions, patients must understand all details about immunotherapy so they…
Malignant pleural mesothelioma is a deadly cancer that is mainly caused by asbestos exposure. It affects the lungs’ lining. It is a very hard to treat cancer because it is very aggressive and is often diagnosed at a late stage. New surgical and therapeutic methods are offering hope though. A recent article looks at pleural…
Primary Outcome Measures Progression free survival Secondary outcome Measures Disease free survival Overall survival Health related quality of life Inclusion Criteria Age ≥ 18 years; Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board); Informed consent for longitudinal observational data collection; Exclusion Criteria Mentally challenged patients that are unable…
Alterations in DNA of patients exposed to asbestos can lead to gene expression, which explains the development of malignant pleural mesothelioma, a rare and aggressive cancer. Scientists were able to analyze public RNA-seq data through a comprehensive bioinformatics pipeline. This led to researchers being able to develop a view of the molecular mechanisms involved in…
Peritoneal mesothelioma is a rare and aggressive cancer linked to asbestos exposure. A promising option for treating the cancer includes cytoreductive surgery (CRS) with heated chemotherapy (HIPEC). A new article explains cytoreductive surgery and HIPEC for the treatment of peritoneal mesothelioma. Cytoreductive surgery removes as many tumors as possible. In the case of peritoneal mesothelioma,…
Malignant pleural mesothelioma is a severe cancer mainly caused by asbestos exposure. It often appears decades after exposure. Early on, symptoms can be unclear, making it difficult to diagnose. Even though the cancer is rare, a mesothelioma diagnosis is still concerning since there is a lack of treatment options. An article looked at 70 mesothelioma…
Results from a clinical trial being performed on malignant pleural mesothelioma patients will be presented at the American Association for Cancer Research meeting being held in Chicago, Illinois. Results will be posted by internationally known mesothelioma expert Dr. Luciano Mutti of the department of Applied Clinical Sciences and Biotechnology at the University of L’Aquila in…
Malignant pleural mesothelioma is a rare and very aggressive cancer with a poor outlook. One cancer treatment has brought hope though. The treatment is known as immune checkpoint inhibitors. There is potential for better outcomes when patients are given this treatment. A new article in Open Respiratory Archives provides a history of recent advances in…
Primary Outcome Measures Establish the recommended phase 2 dose (RP2D) of TNhYP218 CAR T cells based on dose-limiting toxicity (DLT) of defined adverse events (AEs). Determine the preliminary objective response rate of TNhYP218 CAR T cells in a limited number of participants with mesothelioma treated at the recommended phase 2 dose. Secondary Outcome Measures Near…
A mesothelioma diagnosis is hard to receive and can be very overwhelming. Different research outcomes can help doctors and patients make better decisions though. One area of research is blood-based biomarkers. Two biomarkers that can help monitor mesothelioma include mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125). They help monitor mesothelioma progression. A new article…
